Globe Newswire (Mon, 3-Mar 7:00 AM ET)
BioXcel Therapeutics regains compliance with Nasdaq
Seeking Alpha News (Fri, 28-Feb 7:06 AM ET)
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Globe Newswire (Fri, 28-Feb 7:00 AM ET)
BioXcel Therapeutics Announces Reverse Stock Split
Globe Newswire (Thu, 6-Feb 7:00 AM ET)
BioXcel Therapeutics Provides Clinical and Business Update
Globe Newswire (Wed, 5-Feb 7:00 AM ET)
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Bioxcel Therapeutics trades on the NASDAQ stock market under the symbol BTAI.
As of March 3, 2025, BTAI stock price climbed to $4.67 with 140,887,476 million shares trading.
BTAI has a beta of 1.04, meaning it tends to be more sensitive to market movements. BTAI has a correlation of 0.02 to the broad based SPY ETF.
BTAI has a market cap of $14.49 million. This is considered a Sub-Micro Cap stock.
Last quarter Bioxcel Therapeutics reported $214,000 in Revenue and -$5.12 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $2.56.
In the last 3 years, BTAI traded as high as $546.00 and as low as $1.72.
The top ETF exchange traded funds that BTAI belongs to (by Net Assets): VTI, VXF, IWC.
BTAI has underperformed the market in the last year with a return of -91.1%, while the SPY ETF gained +17.8%. In the last 3 month period, BTAI fell short of the market, returning -35.5%, while SPY returned -1.2%. However, in the most recent 2 weeks BTAI has outperformed the stock market by returning +102.2%, while SPY returned -3.3%.
BTAI support price is $1.93 and resistance is $2.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI shares will trade within this expected range on the day.